Your browser doesn't support javascript.
loading
Improving Safety and Outcomes After Allogeneic Hematopoietic Cell Transplantation: A Single-Center Experience.
Salas, Maria Queralt; Pasic, Ivan; Remberger, Mats; Novitzky-Basso, Igor; Law, Arjun Datt; Lam, Wilson; Chen, Carol; Kim, Dennis Dong Hwan; Michelis, Fotios V; Gerbitz, Armin; Viswabandya, Auro; Lipton, Jeffrey Howard; Kumar, Rajat; Mattsson, Jonas.
Afiliación
  • Salas MQ; Department of Medicine, University of Toronto, Toronto, Canada; Hans Messner Allogeneic Transplant Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network. Toronto, Canada; Bone Marrow Transplant Unit, Department of Hematology, IDIBAPS, Hospit
  • Pasic I; Department of Medicine, University of Toronto, Toronto, Canada; Hans Messner Allogeneic Transplant Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network. Toronto, Canada.
  • Remberger M; Department of Medical Sciences, Uppsala University and KFUE, Uppsala University Hospital, Uppsala, Sweden.
  • Novitzky-Basso I; Department of Medicine, University of Toronto, Toronto, Canada; Hans Messner Allogeneic Transplant Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network. Toronto, Canada.
  • Law AD; Department of Medicine, University of Toronto, Toronto, Canada; Hans Messner Allogeneic Transplant Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network. Toronto, Canada.
  • Lam W; Department of Medicine, University of Toronto, Toronto, Canada; Hans Messner Allogeneic Transplant Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network. Toronto, Canada.
  • Chen C; Hans Messner Allogeneic Transplant Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network. Toronto, Canada.
  • Kim DDH; Department of Medicine, University of Toronto, Toronto, Canada; Hans Messner Allogeneic Transplant Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network. Toronto, Canada.
  • Michelis FV; Department of Medicine, University of Toronto, Toronto, Canada; Hans Messner Allogeneic Transplant Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network. Toronto, Canada.
  • Gerbitz A; Department of Medicine, University of Toronto, Toronto, Canada; Hans Messner Allogeneic Transplant Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network. Toronto, Canada.
  • Viswabandya A; Department of Medicine, University of Toronto, Toronto, Canada; Hans Messner Allogeneic Transplant Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network. Toronto, Canada.
  • Lipton JH; Department of Medicine, University of Toronto, Toronto, Canada; Hans Messner Allogeneic Transplant Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network. Toronto, Canada.
  • Kumar R; Department of Medicine, University of Toronto, Toronto, Canada; Hans Messner Allogeneic Transplant Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network. Toronto, Canada.
  • Mattsson J; Department of Medicine, University of Toronto, Toronto, Canada; Hans Messner Allogeneic Transplant Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network. Toronto, Canada; Gloria and Seymour Epstein Chair in Cell Therapy and Transplantation,
Transplant Cell Ther ; 28(5): 265.e1-265.e9, 2022 05.
Article en En | MEDLINE | ID: mdl-35139398
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trasplante de Células Madre Hematopoyéticas / Enfermedad Injerto contra Huésped Tipo de estudio: Guideline Límite: Adult / Humans Idioma: En Revista: Transplant Cell Ther Año: 2022 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trasplante de Células Madre Hematopoyéticas / Enfermedad Injerto contra Huésped Tipo de estudio: Guideline Límite: Adult / Humans Idioma: En Revista: Transplant Cell Ther Año: 2022 Tipo del documento: Article Pais de publicación: Estados Unidos